Healio Minute Podcast, Neurology Edition: Top Headlines - Week of December 5, 2022
Click Here to Manage Email Alerts
In this edition, foslevodopa-foscarbidopa improves motor symptoms in advanced PD, posterior surgery for treating cervical radiculopathy, Tysabri favored over IV in patients with relapsing-remitting MS and more.
Read the full coverage here:
Continuous subcutaneous foslevodopa-foscarbidopa improves motor symptoms in advanced PD
Posterior surgery noninferior to anterior for treating cervical radiculopathy
Subcutaneous delivery of Tysabri favored over IV in patients with relapsing-remitting MS
NeuroLogica receives FDA clearance for multiuse imaging tool
Vumerity effective over 96 weeks in patients with relapsing-remitting MS
References:
Broekema AEH, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.4208.
Gold R, et al. SISTER – subcutaneous: non-interventional, observational, prospective, German multicenter, open-label study over 12-months for Tysabri patient preference – experience from real world – preliminary results of the 1st interim analysis. Presented at: ECTRIMS 2022; Oct. 26-28; Amsterdam.
Singer BA, et al. Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Presented at: ECTRIMS 2022; Oct. 26-28; Amsterdam.
Soileau MJ, et al. Lancet Neurol. 2022;doi:10.1016/S1474-4422(22)00400-8.
Collapse
Click Here to Manage Email Alerts
